AN ACT CONCERNING COST TRANSPARENCY IN LEGEND DRUG ADVERTISEMENTS.

SB 436 requires pharmaceutical companies to disclose in all legend drug advertisements (including direct-to-consumer ads and provider-targeted ads) the portion of the drug's cost attributable to advertising campaigns. This affects drug manufacturers who run such advertisements, mandating transparency about how much advertising expenses contribute to the final price. The key provision compels clear disclosure within the ads themselves, not just in separate documents. The bill aims to provide consumers and healthcare providers with clearer cost information to support informed decisions about medication purchases.